33 results about "Wnt inhibitor" patented technology

Compositions and methods for the treatment of bone diseases, bone fractures, bone injuries and other bone abnormalities involving the use of Dkk protein, a Wnt antagonist, a Wnt inhibitor, or any other related protein for the stimulation or enhancement of mineralization and for stimulating the renewal of cells. One Dkk protein, Dickkopf-2 (Dkk-2), acts to stimulate bone formation independently of Wnt proteins which may be inhibited and / or antagonized by Dkk-2. Dkk-2 displayed enhanced specific targeting ability and enhanced biological activity in stimulating or enhancing mineralization. Dkk-2 also played a role in the differentiation and self-renewal of hematopoietic stem cells and mesenchymal stem cells, particularly in osteoblastogenesis and osteoclastogenesis.

A population of enteroendocrine cells (EEC) is obtained from a mammalian post-natal cell population, such as a population including post-natal stem cells, by treating the population with a plurality of small molecules that upregulate ChgA and promote differentiation of the cells to form the enteroendocrine cells. The upregulation of ChgA is such that the fraction of cells expressing CGA in the obtained cell population, as measured by a ChgA Immunostaining Assay, is at least about 1.5%. Small molecules that can be used to differentiate the post-natal cells into the enteroendocrine cells can include at least one of a Wnt activator, a Notch inhibitor, a Wnt inhibitor, a MEK / ERK inhibitor, a growth factor, a HDAC inhibitor, a Histone Methylation Inhibitor, a Tgf-β inhibitor, and a NeuroD1 activator. Also, the insulin expression of a population of mammalian cells is increased by treating the population with a plurality of small molecules that increase the insulin expression.

The invention discloses an application of a Wnt inhibitor ICG001 in the preparation of medicines for treating hematopoietic aregenerative diseases. The Wnt inhibitor ICG001 can inhibit a CBP mediated Wnt signal path in order to inhibit depletion of too high Wnt signal hematopoietic stem cells, induced by SIRT6 deletion. The invention discloses the application of the Wnt inhibitor ICG001 in the preparation of the medicines for treating hematopoietic aregenerative diseases, and an action mechanism of the ICG001 in promotion of regeneration of SIRT6 knockout hematopoietic stem cells.

The invention provides methods of monitoring differential gene expression of biomarkers to determine patient sensitivity to Wnt inhibitor, methods of determining the sensitivity of a cell to an Wnt inhibitor by measuring biomarkers, methods of screening for candidate Wnt inhibitor, Wnt inhibitor for use in head and neck squamous cell carcinoma.

The present invention provides methods comprising combination therapy for treating cancer. Wnt pathway inhibitors in combination with mitotic inhibitors administered in a staggered or sequential dosing manner for the treatment of cancer and other diseases.

The invention relates to the technical field of biomedicine, in particular to the application of Wnt inhibitor Wnt-C59 in the preparation of medicines for treating dilated cardiomyopathy caused by SCN5A mutation. The present invention proposes for the first time that SCN5A genotype detection is used as an entry point, and the Wnt pathway-specific inhibitor Wnt-C59 is used to inhibit the abnormal activation of the Wnt / β-Catenin pathway caused by the SCN5A gene mutation, so as to improve the dilated cardiomyopathy caused by the SCN5A gene mutation Patient cardiac function prognosis. The experiment established a model of heart dilation induced by aging combined with doxorubicin, and detected the therapeutic effect of Wnt‑C59 on heart dilation by changes in cardiac function and activation of related signaling molecules, so as to provide a theory for the clinical application of Wnt‑C59 in the treatment of dilated cardiomyopathy in accordance with. The invention provides a new treatment method for SCN5A mutation-induced dilated cardiomyopathy, brings dawn to this type of patients, and has a good application prospect.

The invention relates to a method for promoting maturation of myocardial cells differentiated from multipotential stem cells. In the 0-1 day, the multipotential stem cells which are subcultured to bethe 4-5 generation are subjected to induced differentiation, and a culture medium used in the method contains a GSK-3 inhibitor with the concentration being 2-15 mu M / L; in the 2-3 day, the culture medium is used for conducting induced differentiation continuously; in the 4-5 day, a culture medium containing a Wnt inhibitor with the concentration being 2-10 mu M / L is used for conducting induced differentiation; in the 14-20 days, a culture medium containing retinoic acid with the concentration being 0.2-5 mu M / L is used for conducting induced differentiation continuously, later on, the culturemedium is used for conducting induced differentiation culture on the multipotential stem cells, wherein in the 1-6 days, a first induced differentiation culture medium is used and comprises an RPMI-1640 basic culture medium and B27-insulin, after the 7 day, a second induced differentiation culture medium is used and comprises the RPMI-1640 basic culture medium and B27, or in the whole induced differentiation culture process, a CDM3 induced differentiation culture medium or a serum-free induced differentiation culture medium is used, and the CDM3 induced differentiation culture medium comprises the RPMI-1640 basic culture medium, serum albumin, ascorbic acid and double-antibody.

Provided are methods for improving the proliferation and stemness of limbal stem cells (LSCs) by adding a Wnt inhibitor to a medium for limbal explant cultures. When human limbal explants are cultured according to the methods, Wnt / β-catenin signaling is inhibited, resulting in improvement of LSC proliferation, and improvement in the stemness of LSCs, and thus the LSCs may be obtained in high yield.

Provided is a method for producing cerebral cortex neurons from pluripotent stem cells.Provided is a method for producing cerebral cortex neurons from pluripotent stem cells, comprising (i) a step of performing a suspension culture of pluripotent stem cells in a culture medium containing a TGFβ inhibitor, bFGF, a Wnt inhibitor, and a BMP inhibitor, (ii) a step of performing a suspension culture of the cells obtained in the step (i) in a culture medium containing a Wnt inhibitor and a BMP inhibitor, and (iii) a step of further culturing the cells obtained in the step (ii).